Biomarker studies: A call for a comprehensive biomarker study registry

Nature Reviews Clinical Oncology

Volumn 8, Issue 3, 2011, Pages 171-176

  Andre, Fabrice ^a   McShane, Lisa M ^b   Michiels, Stefan ^c   Ransohoff, David F ^d   Altman, Douglas G ^e   Reis Filho, Jorge S ^e   Hayes, Daniel F ^f   Pusztai, Lajos ^g  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b NATIONAL CANCER INSTITUTE   (United States)

^c JULES BORDET INSTITUTE   (Belgium)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^g UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; CANCER REGISTRY; CANCER RESEARCH; HUMAN; HYPOTHESIS; MEDICAL LITERATURE; PRIORITY JOURNAL; PUBLICATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYSTEMATIC ERROR;

HUMANS; NEOPLASMS; REGISTRIES; TUMOR MARKERS, BIOLOGICAL;

EID: 79952434787     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.4     Document Type: Article

References (25)

1. Begg, C. et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 276, 637-639 (1996). (Pubitemid 26278070)
2. McCray, A. T. & Ide, N. C. Design and mplementation of a national clinical trials registry. J. Am. Med. Inform. Assoc. 7, 313-323 (2000). (Pubitemid 30314119)
3. Altman, D. G. & Riley, R. D. Primer: an evidence-based approach to prognostic markers. Nat Clin. Pract Oncol. 2, 466-472 (2005). (Pubitemid 41679099)
4. Simon, R. M., Paik, S. & Hayes, D. F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl Cancer Inst 101, 1446-1452 (2009).
5. Simon, R. Development and evaluation of therapeutically relevant predictive classifiers using gene expression profiling. J. Natl Cancer Inst 98, 1169-1171 (2006). (Pubitemid 44390987)
6. Simon, R. Development and validation of therapeutically relevant multi-gene biomarker classifiers. J. Natl Cancer Inst 97, 866-867 (2005). (Pubitemid 41417930)
7. Simon, R. & Altman, D. G. Statistical aspects of prognostic factor studies in oncology. Br. J. Cancer 69, 979-985 (1994). (Pubitemid 24161844)
8. McShane, L. M. et al. Reporting recommendations for tumor marker prognostic studies (REMARK). Nat Clin. Pract Oncol. 2, 416-422 (2005). (Pubitemid 43115010)
9. Song, F. et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol. Assess. 14, 1-193 (2010).
10. Kyzas, P A., Loizou, K. T. & Ioannidis, J. P. Selective reporting biases in cancer prognostic factor studies. J. Natl Cancer Inst 97, 1043-1055 (2005). (Pubitemid 41417921)
11. Penault-Llorca, F. et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 27, 2809-2815 (2009).
12. nd edn (eds Gospodarowicz, M. K., Henson, D. E. & Hutter, R. V. P. et al.) 49-56 (Wiley-Liss, New York, 2001).
13. Simon, R. M., Paik, S. & Hayes, D. F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl Cancer Inst 101, 1446-1452 (2009).
14. Hayes, D. F. et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl Cancer Inst. 88, 1456-1466 (1996). (Pubitemid 26340047)
15. De Angelis, C. et al. International Committee of Medical Journal Editors. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N. Engl. J. Med. 351, 1250-1251 (2004). (Pubitemid 39296312)
16. Zarin, D. A., Tse, T. & Ide, N. C. Trial Registration at ClinicalTrials.gov between May and October 2005. N. Engl. J. Med. 353, 2779-2787 (2005). (Pubitemid 43016817)
17. Mathieu, S., Boutron, I., Moher, D., Altman, D. G. & Ravaud, P. Comparison of registered and published primary outcomes in randomized controlled trials. JAMA 302, 977-984 (2009).
18. Ross, J. S., Mulvey, G. K., Hines, E. M., Nissen, S. E. & Krumholz, H. M. Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med. 6, e1000144 (2009).
19. Williams, R. J., Tse, T., Harlan, W. R. & Zarin, D. A. Registration of observational studies: is it time? CMAJ 182, 1638-1642 (2010).
20. Ioannidis, J. P Why most published research findings are false. PLoS Med. 2, e124 (2005).
21. Simon, R. et al. Design and analysis of DNA microarray investigations. (Springer-Verlag, New York, 2004).
22. Conforti, R. et al. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Ann. Oncol. 18, 1477-1483 (2007). (Pubitemid 47365479)
23. Andre, F. et al. CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist 14, 1182-1188 (2009).
24. Meslin, F. et al. Efficacy of adjuvant chemotherapy according to Prion protein expression in patients with estrogen receptor-negative breast cancer. Ann. Oncol. 18, 1793-1798 (2007). (Pubitemid 350111566)
25. Andre, F. et al. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann. Oncol. 19, 315-320 (2008). (Pubitemid 351201713)